Acasti Announces Definitive Agreement to Acquire Grace Therapeutics, Inc.

Investor Relations

Latest Financial Results

FY 2021

Fiscal Year Ended Mar 31, 2021

Latest Annual Filing

Fiscal Year Ended Mar 31, 2021

View Filing

Stock Information

Company Overview

Acasti Pharma is a biopharmaceutical innovator that has historically focused on advancing a potentially best-in-class cardiovascular drug, CaPre® (omega-3 phospholipid), for the treatment of hypertriglyceridemia, a chronic condition affecting an estimated one third of the U.S. population. Since its founding in 2008, Acasti Pharma has focused on addressing a critical market need for an effective, safe and well-absorbing omega-3 therapeutic that can make a positive impact on the major blood lipids associated with cardiovascular disease risk. Acasti conducted two Phase 3 clinical trials: the TRILOGY trials. In TRILOGY 1, CaPre® achieved a 30.5% reduction in triglyceride levels at 12 weeks and 36.7% reduction in triglyceride levels at 26 weeks, as well as 42.2% reduction in triglyceride levels among patients receiving CaPre while on background statin therapy at 12 weeks. Despite positive results in the CaPre arm, the TRILOGY 1 study did not reach statistical significance. In TRILOGY 2, CaPre achieved 30.4% median reduction in triglycerides at 12 weeks and 38.4% at 26 weeks, but did not achieve statistical significance for the primary endpoint.

Acasti-Grace Acquisition: Investor Presentation - June 2021

Acasti-Grace Acquisition: Investor Presentation - June 2021

Download Acasti-Grace Acquisition: Investor Presentation - June 2021


Having accumulated decades of collective experience across a variety of fields, our leadership team is the source of our success.

Investor Contact Information


Acasti Pharma Inc.
3009 Boul. de la Concorde E.
Suite 102
Laval, Québec H7E 2B5

Investor Relations

Crescendo Communications, LLC
Chrysler Building
405 Lexington Ave
9th Floor, Suite 9034
New York, NY 10174
T: 212-671-1020

Transfer Agent

Computershare Trust Company of Canada
650 de Maisonneuve West
7th Floor
Montreal, QC H3A 3T2
T: 514-982-7888